Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Merits and pitfalls of mifepristone in Cushing's syndrome

Castinetti, F, Fassnacht, M, Johanssen, S, Terzolo, M, Bouchard, P, Chanson, P, Do Cao, C, Morange, I, Picó, A, Ouzounian, S, Young, J, Hahner, S, Brue, T, Allolio, B, Conte-Devolx, B·2009·European Journal of Endocrinology

Abstract

Objective: Mifepristone is the only available glucocorticoid receptor antagonist. Only few adult patients with hypercortisolism were treated to date by this drug. Our objective was to determine effectiveness and tolerability of mifepristone in Cushing's syndrome (CS). Design: Retrospective study of patients treated in seven European centers. Methods: Twenty patients with malignant (n=15, 12 with adrenocortical carcinoma, three with ectopic ACTH secretion) or benign (n=5, four with Cushing's disease, one with bilateral adrenal hyperplasia) CS were treated with mifepristone. Mifepristone was initiated with a median starting dose of 400 mg/day (200–1000). Median treatment duration was 2 months (0.25–21) for malignant CS, and 6 months (0.5–24) for benign CS. Clinical (signs of hypercortisolism, blood pressure, signs of adrenal insufficiency), and biochemical parameters (serum potassium and glucose) were evaluated. Results: Treatment was stopped in one patient after 1 week due to severe uncontrolled hypokalemia. Improvement of clinical signs was observed in 11/15 patients with malignant CS (73%), and 4/5 patients with benign CS (80%). Psychiatric symptoms improved in 4/5 patients within the first week. Blood glucose levels improved in 4/7 patients. Signs of adrenal insufficiency were observed in 3/20 patients. Moderate to severe hypokalemia was observed in 11/20 patients and increased blood pressure levels in 3/20 patients. Conclusion: Mifepristone is a rapidly effective treatment of hypercortisolism, but requires close monitoring of potentially severe hypokalemia, hypertension, and clinical signs of adrenal insufficiency. Mifepristone provides a valuable treatment option in patients with severe CS when surgery is unsuccessful or impossible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-09-0098

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 163

Metadata

Authors
Castinetti, F., Fassnacht, M., Johanssen, S., Terzolo, M., Bouchard, P., Chanson, P., Do Cao, C., Morange, I., Picó, A., Ouzounian, S., Young, J., Hahner, S., Brue, T., Allolio, B., & Conte-Devolx, B.
Venue
European Journal of Endocrinology
Published
2009-06
Volume
160
Issue
6
Pages
1003-1010
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2138315222
Cited by
163
References
4
FWCI
9.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Merits and pitfalls of mifepristone in Cushing's syndrome. https://app.cochat.ai/papers/10.1530/eje-09-0098
The paper
Castinetti, F., Fassnacht, M., Johanssen, S., Terzolo, M., Bouchard, P., Chanson, P., Do Cao, C., Morange, I., Picó, A., Ouzounian, S., Young, J., Hahner, S., Brue, T., Allolio, B., & Conte-Devolx, B. (2009). Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology. https://doi.org/10.1530/eje-09-0098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.